Macquarie Group’s GSK GSK Stock Holding History

Macquarie Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-37,750	Closed	-$1.63M	–	1115
2025 Q3	$1.63M	Buy	37,750 +16,990	+82%	+$664K	﹤0.01%	1230
2025 Q2	$797K	Sell	20,760 -1,718	-8%	-$65.6K	﹤0.01%	1397
2025 Q1	$871K	Buy	+22,478	New	+$823K	﹤0.01%	1408
2024 Q4	–	Sell	-13,719	Closed	-$561K	–	1685
2024 Q3	$561K	Sell	13,719 -454,251	-97%	-$18.6M	﹤0.01%	1462
2024 Q2	$18M	Sell	467,970 -554,101	-54%	-$23.3M	0.02%	677
2024 Q1	$43.8M	Sell	1,022,071 -108,328	-10%	-$4.47M	0.05%	465
2023 Q4	$41.9M	Sell	1,130,399 -573,354	-34%	-$20.6M	0.05%	487
2023 Q3	$61.8M	Sell	1,703,753 -71,192	-4%	-$2.53M	0.08%	340
2023 Q2	$63.3M	Buy	1,774,945 +384,558	+28%	+$13.8M	0.07%	356
2023 Q1	$49.5M	Buy	1,390,387 +302,731	+28%	+$10.6M	0.06%	429
2022 Q4	$38.2M	Sell	1,087,656 -116,819	-10%	-$3.89M	0.05%	526
2022 Q3	$35.4M	Sell	1,204,475 -419,521	-26%	-$15.9M	0.04%	539
2022 Q2	$88.4M	Sell	1,623,996 -195,126	-11%	-$10.8M	0.1%	274
2022 Q1	$99.1K	Sell	1,819,122 -177,657	-9%	-$9.65M	0.08%	296
2021 Q4	$110M	Sell	1,996,779 -170,465	-8%	-$8.87M	0.09%	282
2021 Q3	$104M	Sell	2,167,244 -164,918	-7%	-$8.28M	0.09%	290
2021 Q2	$116M	Buy	2,332,162 +319,438	+16%	+$15.3M	0.1%	267
2021 Q1	$89.8M	Buy	2,012,724 +541,535	+37%	+$24.6M	0.13%	182
2020 Q4	$67.7M	Sell	1,471,189 -83,875	-5%	-$3.85M	0.1%	242
2020 Q3	$73.2M	Sell	1,555,064 -75,947	-5%	-$3.81M	0.12%	175
2020 Q2	$83.2M	Sell	1,631,011 -78,671	-5%	-$4.04M	0.14%	147
2020 Q1	$81M	Sell	1,709,682 -59,112	-3%	-$3.15M	0.17%	115
2019 Q4	$104M	Sell	1,768,794 -25,665	-1%	-$1.43M	0.15%	116
2019 Q3	$95.7M	Sell	1,794,459 -70,315	-4%	-$3.62M	0.16%	107
2019 Q2	$93.3M	Sell	1,864,774 -255,004	-12%	-$12.8M	0.16%	116
2019 Q1	$111M	Buy	2,119,778 +90,632	+4%	+$4.53M	0.19%	92
2018 Q4	$96.9M	Buy	2,029,146 +7,714	+0.4%	+$380K	0.19%	94
2018 Q3	$102M	Buy	2,021,432 +78,358	+4%	+$3.98M	0.17%	108
2018 Q2	$97.9M	Sell	1,943,074 -18,561	-0.9%	-$935K	0.17%	111
2018 Q1	$95.8M	Buy	1,961,635 +210,607	+12%	+$9.81M	0.17%	108
2017 Q4	$77.6M	Sell	1,751,028 -164,462	-9%	-$7.6M	0.14%	133
2017 Q3	$97.2M	Sell	1,915,490 -45,544	-2%	-$2.31M	0.17%	108
2017 Q2	$106M	Sell	1,961,034 -70,868	-3%	-$3.78M	0.19%	82
2017 Q1	$107M	Buy	2,031,902 +95,920	+5%	+$4.87M	0.19%	82
2016 Q4	$93.2M	Sell	1,935,982 -952,691	-33%	-$47.1M	0.18%	88
2016 Q3	$156M	Sell	2,888,673 -3,207,821	-53%	-$176M	0.3%	58
2016 Q2	$330M	Buy	6,096,494 +3,005,712	+97%	+$158M	0.32%	56
2016 Q1	$157M	Buy	3,090,782 +160,730	+5%	+$8.01M	0.32%	62
2015 Q4	$148M	Sell	2,930,052 -210,316	-7%	-$10.7M	0.3%	68
2015 Q3	$151M	Buy	3,140,368 +10,202	+0.3%	+$531K	0.32%	68
2015 Q2	$163M	Buy	3,130,166 +414,884	+15%	+$23.4M	0.32%	70
2015 Q1	$157M	Buy	2,715,282 +158,433	+6%	+$9.08M	0.31%	71
2014 Q4	$137M	Sell	2,556,849 -180,293	-7%	-$10.1M	0.28%	77
2014 Q3	$157M	Buy	2,737,142 +981,244	+56%	+$60.2M	0.34%	68
2014 Q2	$117M	Buy	1,755,898 +114,882	+7%	+$7.78M	0.26%	89
2014 Q1	$110M	Buy	1,641,016 +43,324	+3%	+$2.93M	0.19%	103
2013 Q4	$107M	Buy	1,597,692 +274,867	+21%	+$17.8M	0.19%	100
2013 Q3	$83M	Sell	1,322,825 -11,436	-0.9%	-$736K	0.16%	113
2013 Q2	$83.3M	Buy	+1,334,261	New	+$84.7M	0.18%	106

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Macquarie Group's GSK Position: Q4 2025 in Review

Macquarie Group sold out of GSK (GSK) in Q4 2025, closing a stake of 37,750 shares — an estimated $1.63M sold.

Macquarie Group first reported a position in GSK in Q2 2013 and held it in 49 quarters. The position peaked at $330M in Q2 2016. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Macquarie Group reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 37,750 GSK shares in Q4 2025, an estimated $1.63M.
Macquarie Group first reported a position in GSK in Q2 2013 and held it in 49 quarters.
Macquarie Group's GSK position peaked at $330M in Q2 2016.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.